Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-510 in Advanced Mesothelin-Expressing Cancer
NCT05451849Phase 2Terminated
- Sponsor
- TCR2 Therapeutics Inc.
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of TC-510 in mesothelioma, ovarian cancer, pancreatic cancer (PC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), sponsored by TCR2 Therapeutics Inc.. Started Jun 2022; status: terminated.
02
Drugs
TC-510
03
Conditions
mesotheliomaovarian cancerpancreatic cancer (PC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05451849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451849.